RxDoctor Payments Data

Keturah Bell, MD

Family Medicine · Shelby, NCNPI 1134213283

Payments from drug & device makers

$562in general payments, 2019–2025

Across 31 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$254
  • GSK$104
  • AstraZeneca$35
  • Exact Sciences$28
  • Inari Medical, Inc.$25
  • Phathom Pharmaceuticals, Inc.$21
  • plus $96 from 6 others

What the payments were for

  • Food & beverage$562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$562 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$102,515
Medicare patients
247
Services billed
1,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$126,937
EliquisApixaban106$107,414
JardianceEmpagliflozin53$52,787
TrulicityDulaglutide25$28,382
MounjaroTirzepatide27$28,375
FarxigaDapagliflozin Propanediol18$27,778
EntrestoSacubitril/Valsartan19$23,267
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$21,655
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$21,562
JanuviaSitagliptin Phosphate20$20,446
Tresiba Flextouch U-200Insulin Degludec21$18,767
Spiriva HandihalerTiotropium Bromide25$15,170
XareltoRivaroxaban18$14,174
Tresiba Flextouch U-100Insulin Degludec22$12,061
Breo ElliptaFluticasone/Vilanterol15$10,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$254$126,937113 claims
Lilly USA, LLCTrulicity, Mounjaro$17$56,75652 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$35$55,69871 claims
GSKTrelegy Ellipta, Breo Ellipta$104$32,37449 claims
Johnson & JohnsonXarelto$13$14,17418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →